glp-1 ro.com Ro launches supply tracker to help patients navigate shortages Ro, Amgen probe insurance roadblocks
Description
Take our quick 2-minute assessment
60 Patients treated with exenatide once weekly experienced significantly higher rates of injection-site related adverse events (22.0%) compared to patients treated with exenatide twice daily (12.7%)
Although Sterigenics denies wrongdoing and maintains its Willowbrook operations did not pose a safety risk, the company acknowledged the financial risk of continuing litigation
[DOI] [PMC free article] [PubMed] [Google Scholar] 116.Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL
